Real-World Outcomes of [¹⁷⁷Lu]Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors: Data from a Belgian ENETS Center of Excellence
Post-marketing analysis in an ENETS Center of Excellence confirmed that the efficacy and safety of PRRT in GEPNETs are consistent with phase 3 trial data.
Authors
- Ioannis Karfis (ORCID: https://orcid.org/0000-0003-2158-3981)
- Paulus Kristanto (ORCID: https://orcid.org/0000-0002-1657-5250)
- Ringo Manta (ORCID: https://orcid.org/0000-0002-2933-5416)
- Magdalena Mileva (ORCID: https://orcid.org/0000-0002-9929-4576)
- Carlos Trucharte Artigas
- Zéna Wimana (ORCID: https://orcid.org/0000-0002-8443-7765)
- P Flamen
- A Hendlisz
- I Lazarenko
- J L Van Laethem
Institutions
- Université Libre de Bruxelles (BE)
- Institut Jules Bordet (BE)
- Grand Charleroi Hospital (BE)
Publication Details
- Journal
- Acta Gastro Enterologica Belgica
- Published
- 2026-03-02
- DOI
- https://doi.org/10.51821/89.1.14882
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00